Teva Pharmaceutical Industries Ltd.

Major Shareholding Notification • Feb 1, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Drapé Eric	2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	3. Date of Earliest Transaction (Month/Day/Year) 01/30/2024	X Officer (give title below) Other (specify below) Executive VP Global Operations
(Street) Tel Aviv, L3 6944020 (City) (State) (Zip)	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security	2. Transaction	12A. Deemed	3. Transaction		4. Securities Acquired			5. Amount of Securities Beneficially		7. Nature
(Instr. 3)	Date	Execution Date, if Code						(A) or Disposed of (D) Owned Following Reported	Ownership of Indirect
	(Month/Day/Year) any		(Instr. 8)		(Instr. 3, 4 and 5)			Transaction(s)	Form:	l Beneficial
		(Month/Day/Year)						(Instr. 3 and 4)		Direct (D) Ownership
									or Indirect (Instr. 4)
						(A) or			(1)
			Code		Amount	D)	Price		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

e.g. , puts, calls, warrants, options, convertible securities)
1. Title of	2	3. Transaction	3A. Deemed	4.		5. Number		6. Date Exercisable		7. Title and Amount			8. Price of 9. Number of	10	11. Nature
Derivative	Conversion Date							Execution Date, if Transaction of Derivative and Expiration Date		of Underlying			Derivative Derivative	Ownership of Indirect
Security		or Exercise (Month/Day/Year)	any	Code		Securities		(Month/Day/Year)		Securities		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year) (Instr. 8)			Acquired				(Instr. 3 and 4)		(Instr. 5)	Beneficially		Derivative Ownership
	Derivative					(A) or						Owned	Security:	(Instr. 4)
	Security					Disposed of							Following	Direct (D)
						(D)							Reported	or Indirect
						(Instr. 3, 4,							Transaction(s)	(D)
					and 5)							(Instr. 4)	(Instr. 4)
											Amount
								Date	Expiration	Title	Or Number
								Exercisable Date			of
											Shares
				Code		(A)	(D)
Restricted										Ordinary
Share	(1)	01/30/2024		A		55,226		(2)	(2)	Shares	55,226	\$ 0	55,226	D
Units										(3)

Explanation of Responses:

• 1. Each restricted share unit represents a continent, one ordinary share or, at the option of the Human Resources and Committer, the cash vale of one ordinary share.
• 1. Represents restricted share units received of performance share units. These units . These units remain subject to time-based vall vell vell vell vill vest on March 5, 2024.
• 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Eric Drape 02/01/2024

Date

* Signature of Reporting Person

FORM

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative

defense conditions of Rule 10b5-1(c) See Instruction 10. (Print or Type Responses)

• * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
• ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 78f(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information in this form are not required to respond unless the form displays a currently valid OMB Number.